Project B: Support indication selection for HyperMabs’ developmental therapeutic by building translational rationale for target prevalence.

HyperMabs is a protein engineering company focused on the development of therapeutics for diseases with high unmet need including Covid-19.
The role of the Translational Science Team is to discover and develop biomarkers that indicate pharmacodynamic response to the company’s therapeutics as well as support the relevance of the targeted biological pathways in diseases of interest (indication selection).
The goal of the two MITACS projects within HyperMabs’ Translational Science Department is to develop and validate scientific methods (i) for sample collection to gain insight into pharmacodynamic biomarkers and (ii) to analyse the relevance of the company’s drug targets in a range of diseases. The results of the project will add value to the company’s ongoing efforts in rapidly developing drugs for serious diseases.

Faculty Supervisor:

Elias Georges

Student:

Partner:

HyperMabs Inc

Discipline:

Life Sciences

Sector:

Professional, scientific and technical services

University:

McGill University

Program: